1 / 11

Rivastigmine Market Analysis | Coherent Market Insights

Read here the press release report on u201cRivastigmine Marketu201d published by CMI team.<br><br>

athiranair23
Télécharger la présentation

Rivastigmine Market Analysis | Coherent Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market InsightS Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. Rivastigmine Market Analysis (2020-2027) • Rivastigmine is a cholinesterase enzyme inhibitor, which acts on butylcholinesterase and acetylcholinesterase. It is a cholinergic agent that aids in the treatment of Alzheimer’s and Parkinson’s disease. The drug can be administered orally or in transdermal patches form, owing to its small molecular size.

  3. Rivastigmine Market – Dynamics • Increasing geriatric population is a major driver for growth of the rivastigmine market. According to The Alzheimer Association, in 2018, the risk of suffering from dementia can increase double fold above the age of 65 years in every 5 years. Moreover, increasing prevalence of cardiovascular diseases worldwide also accounts for the development of Alzheimer’s disease, thereby boosting demand for rivastigmine. As per the National Center for Biotechnology Information published in 2013, the incidence of cardiovascular diseases was around 22.5 per 1,000 person worldwide which in turn suggesting a risk of dementia.Diseases such as diabetes and blood pressure can also increase the risk of dementia, which further boosts demand for rivastigmine, thereby propelling the market growth.

  4. Rivastigmine Market – Regional Insights • The rivastigmine market is segregated geographically into North America, Latin America, Asia Pacific, Europe, Middle East, and Africa. North America accounted for the largest share in the global rivastigmine market in 2017. This is owing to increasing prevalence of chronic kidney disease in the region that may lead to dementia. According to The American Kidney Fund, around 31 million people suffered from chronic kidney disease in 2015. Europe accounted for the second largest share in terms of revenue in the global rivastigmine market, in 2017 owing to increasing geriatric population in the region. Geriatric population is more prone to dementia. According to World Population Prospects (WPP), in 2017, around 25% of the population in Europe was aged 60 years or above. According to the Alzheimer’s Association, in 2017, there was significant prevalence of vascular diseases in Latin America and Africa. Therefore, Latin America and Africa are expected to witness significant growth in the global rivastigmine market during the forecast period.

  5. Rivastigmine Market – Competitive Landscape • Major players operating in the global rivastigmine market include, Novartis Europharm Limited, ActavisPharma, Apotex Corporation, Aurobindo Pharm Ltd, Teva Pharmaceuticals Industries Ltd, Dr. Reddy’s Laboratories, Macleods, and others. Key players in the market are focused on product development and approvals in order to enhance their market share. For instance, in 2007, U.S. FDA approved Exelon (Rivastigminetartarate) — developed by Novartis Europharm Limited for the treatment of Alzheimer's and Parkinson's disease.

  6. Global Rivastigmine Market Taxonomy: • On the basis of disease indication, the global rivastigmine market is segmented into: • Alzheimer’s disease • Parkinson’s disease • On the basis of formulation, the global rivastigmine market is segmented into: • Capsules • Transdermal Patches • On the basis of distribution channel, the global rivastigmine market is segmented into: • Hospital pharmacies • Retail pharmacies • Online pharmacies

  7. s • On the basis of geography, the global rivastigmine market is segmented into: • North America • Latin America • Europe • Asia Pacific • Middle East • Africa

  8. Request sample copy here • Request PDF brochure here • Request Customization here • Talk to Analyst • Buy Now • Reference: • https://www.coherentmarketinsights.com/ongoing-insight/rivastigmine-market-2407

  9. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. • What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  10. Contact Us: • Mr. Shah • Coherent Market Insights Pvt. Ltd. • Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S. • Phone: +1-206-701-6702 • Email :sales@coherentmarketinsights.com

  11. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related